Improving data sharing to increase the efficiency of antibiotic R&D
Greater investment is needed in antibiotic R&D, and more must be done to maximize the impact of such investments. More widespread data sharing, ...
Fighting the dangerous increase of multi drug-resistant Microbes
In 1928, Alexander Fleming discovered penicillin, which would become the first commercialized antibiotic. Ever since, germs have...
New partnership to tackle threat of superbugs
West Coast, USA-based Forge Therapeutics has inked a deal with Switzerland's Basilea Pharmaceutica to...
Forge Therapeutics, Basilea Pharmaceutica partner on antibiotics
San Diego’s Forge Therapeutics has partnered with Basilea Pharmaceutica to develop antibiotics for the Swiss drug company. The deal gives Forge the opportunity ...
Forge Therapeutics, Basilea Sign Deal to Pursue New Antibiotics
Forge Therapeutics, founded in 2015 with the goal of developing drugs that target metalloenzymes, said Wednesday it had agreed to let Basilea Pharmaceutica ...
Forge Therapeutics Gets up to $11.1M to Advance “Superbug” Drugs
As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat ...
Antibiotic companies seek success by learning from each others’ failures
San Diego's Forge Therapeutics will get information from another company’s unsuccessful effort to develop antibiotics, under a new government-sponsored initiative to help others ...
Anti-flu drug exploits weakness in H3N2 strain
More than 65,000 Americans have been victims of influenza A H3N2 this season, according the Centers for Disease Control. And this particular strain ...
Antibiotic developer Forge Therapeutics expanding into new space
From about 1,000 square feet in a business incubator, antibiotic developer Forge Therapeutics has moved to a 7,000 square-foot headquarters. The tiny La Jolla ...
Forge Therapeutics expands footprint in San Diego
On Monday, local leaders converged to celebrate a true San Diego success story: Forge Therapeutics. The biotech startup is doubling its local footprint ...